Kidney Cancer UK   Report issue

Foundation Phase 3
Founded: Cambridge MA United States (2000)

Organization Overview

First Clinical Trial
2018
NCT03288532
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Kidney Cancer UK

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Renal Cell (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 6